Composition contains a)(3,5-bis trifluoro¬methyl)-N-[4-pyridin-3-yl pyridin-2-ylamino) phe¬nyl]-benzamide or pharmaceutically acceptable salts therein therapeutically effective amount; b) lipophilic phase; c) pharmaceutically acceptable surface-active material and d) pharmaceutically acceptable solvent mixed with water. Provided method for: preparation of composition and application thereat the treatment of human or animal cancer; or medicine preparation. Table: 19